Dorchester Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Dorchester Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,100	Closed	-$207K	–	115
2015 Q4	$207K	Buy	4,100 +500	+14%	+$24.7K	0.09%	103
2015 Q3	$220K	Hold	3,600	–	–	0.08%	106
2015 Q2	$262K	Buy	+3,600	New	+$206K	0.09%	108

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Dorchester Wealth Management's PBE Position: Q1 2016 in Review

Dorchester Wealth Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2016, closing a stake of 4,100 shares — an estimated $207K sold.

Dorchester Wealth Management first reported a position in PBE in Q2 2015 and held it in 3 quarters. The position peaked at $262K in Q2 2015. 71 funds tracked by Wall St. Rank hold PBE as of Q1 2016.

Dorchester Wealth Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2016 after selling out during the quarter.
Dorchester Wealth Management sold 4,100 Invesco Biotechnology & Genome ETF shares in Q1 2016, an estimated $207K.
Dorchester Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2015 and held it in 3 quarters.
Dorchester Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $262K in Q2 2015.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2016.

Based on Dorchester Wealth Management's 13F filing for Q1 2016, filed 18 Apr 2016.